

# Lorena Lorefice

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8162646/publications.pdf>

Version: 2024-02-01

66  
papers

1,565  
citations

331538

21  
h-index

345118

36  
g-index

67  
all docs

67  
docs citations

67  
times ranked

2755  
citing authors

#	ARTICLE	IF	CITATIONS
1	Overexpression of the Cytokine BAFF and Autoimmunity Risk. <i>New England Journal of Medicine</i> , 2017, 376, 1615-1626.	13.9	301
2	<sup>1</sup> H-NMR analysis provides a metabolomic profile of patients with multiple sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2016, 3, e185.	3.1	68
3	Epidemiology of multiple sclerosis in south-western Sardinia. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1282-1289.	1.4	66
4	The risk of Bipolar Disorders in Multiple Sclerosis. <i>Journal of Affective Disorders</i> , 2014, 155, 255-260.	2.0	61
5	Clinical assessment of gait in individuals with multiple sclerosis using wearable inertial sensors: Comparison with patient-based measure. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 10, 187-191.	0.9	61
6	mRNA COVID-19 vaccines do not increase the short-term risk of clinical relapses in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 448-450.	0.9	53
7	What do multiple sclerosis patients and their caregivers perceive as unmet needs?. <i>BMC Neurology</i> , 2013, 13, 177.	0.8	48
8	Metabolomic analysis identifies altered metabolic pathways in Multiple Sclerosis. <i>International Journal of Biochemistry and Cell Biology</i> , 2017, 93, 148-155.	1.2	44
9	Multiple sclerosis and bipolar disorders: The burden of comorbidity and its consequences on quality of life. <i>Journal of Affective Disorders</i> , 2014, 167, 192-197.	2.0	40
10	Top-down proteomic profiling of human saliva in multiple sclerosis patients. <i>Journal of Proteomics</i> , 2018, 187, 212-222.	1.2	40
11	Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?. <i>Neurotherapeutics</i> , 2020, 17, 200-207.	2.1	39
12	Vitamin D Responsive Elements within the HLA-DRB1 Promoter Region in Sardinian Multiple Sclerosis Associated Alleles. <i>PLoS ONE</i> , 2012, 7, e41678.	1.1	38
13	Long-term follow-up of pediatric MS patients starting treatment with injectable first-line agents: A multicentre, Italian, retrospective, observational study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 399-407.	1.4	38
14	Treatment of multiple sclerosis with rituximab: A multicentric Italian-Swiss experience. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1519-1531.	1.4	38
15	Influence of treatments in multiple sclerosis disability: A cohort study. <i>Multiple Sclerosis Journal</i> , 2015, 21, 433-441.	1.4	32
16	Efficacy and safety of alemtuzumab in a real-life cohort of patients with multiple sclerosis. <i>Journal of Neurology</i> , 2019, 266, 1405-1411.	1.8	31
17	The impact of visible and invisible symptoms on employment status, work and social functioning in Multiple Sclerosis. <i>Work</i> , 2018, 60, 263-270.	0.6	30
18	A cross-sectional and longitudinal study evaluating brain volumes, RNFL, and cognitive functions in MS patients and healthy controls. <i>BMC Neurology</i> , 2018, 18, 67.	0.8	27

#	ARTICLE	IF	CITATIONS
19	Are static and functional balance abilities related in individuals with Multiple Sclerosis?. Multiple Sclerosis and Related Disorders, 2017, 15, 1-6.	0.9	26
20	The burden of multiple sclerosis and patientsâ€™ coping strategies. BMJ Supportive and Palliative Care, 2018, 8, 38-40.	0.8	25
21	Interaction between HLA-DRB1-DQB1 Haplotypes in Sardinian Multiple Sclerosis Population. PLoS ONE, 2013, 8, e59790.	1.1	25
22	PML in a person with multiple sclerosis. Neurology, 2018, 90, 83-85.	1.5	23
23	Multi-Platform Characterization of Cerebrospinal Fluid and Serum Metabolome of Patients Affected by Relapsingâ€“Remitting and Primary Progressive Multiple Sclerosis. Journal of Clinical Medicine, 2020, 9, 863.	1.0	22
24	Intrathecal oligoclonal bands synthesis in multiple sclerosis: is it always a prognostic factor?. Journal of Neurology, 2018, 265, 424-430.	1.8	21
25	Assessing the burden of vascular risk factors on brain atrophy in multiple sclerosis: A case- control MRI study.. Multiple Sclerosis and Related Disorders, 2019, 27, 74-78.	0.9	20
26	Post-natalizumab clinical and radiological findings in a cohort of multiple sclerosis patients: 12-month follow-up. Neurological Sciences, 2014, 35, 401-408.	0.9	19
27	Assessing the Metabolomic Profile of Multiple Sclerosis Patients Treated with Interferon Beta 1a by 1H-NMR Spectroscopy. Neurotherapeutics, 2019, 16, 797-807.	2.1	17
28	Fatigue, as measured using the Modified Fatigue Impact Scale, is a predictor of processing speed improvement induced by exercise in patients with multiple sclerosis: data from a randomized controlled trial. Journal of Neurology, 2018, 265, 1328-1333.	1.8	15
29	New horizons for multiple sclerosis therapeutics: milestones in the development of ocrelizumab. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 1093-1099.	1.0	15
30	Does Multiple Sclerosis Differently Impact Physical Activity in Women and Man? A Quantitative Study Based on Wearable Accelerometers. International Journal of Environmental Research and Public Health, 2020, 17, 8848.	1.2	15
31	Is Geo-Environmental Exposure a Risk Factor for Multiple Sclerosis? A Population-Based Cross-Sectional Study in South-Western Sardinia. PLoS ONE, 2016, 11, e0163313.	1.1	15
32	Progressive multiple sclerosis and mood disorders. Neurological Sciences, 2015, 36, 1625-1631.	0.9	14
33	Autoimmune comorbidities in multiple sclerosis: what is the influence on brain volumes? A caseâ€“control MRI study. Journal of Neurology, 2018, 265, 1096-1101.	1.8	14
34	Characteristics and treatment of Multiple Sclerosis-related trigeminal neuralgia: An Italian multi-centre study. Multiple Sclerosis and Related Disorders, 2020, 37, 101461.	0.9	14
35	â€“Timed up and goâ€™ and brain atrophy: a preliminary MRI study to assess functional mobility performance in multiple sclerosis. Journal of Neurology, 2017, 264, 2201-2204.	1.8	13
36	Perception of risk and shared decision making process in multiple sclerosis. Expert Review of Neurotherapeutics, 2017, 17, 173-180.	1.4	13

#	ARTICLE	IF	CITATIONS
37	Role of interferon-beta in Mycobacterium avium subspecies paratuberculosis antibody response in Sardinian MS patients. <i>Journal of the Neurological Sciences</i> , 2015, 349, 249-250.	0.3	12
38	Effects of Pregnancy and Breastfeeding on Clinical Outcomes and MRI Measurements of Women with Multiple Sclerosis: An Exploratory Real-World Cohort Study. <i>Neurology and Therapy</i> , 2022, 11, 39-49.	1.4	12
39	Charcot-Marie-Tooth disease: genetic subtypes in the Sardinian population. <i>Neurological Sciences</i> , 2017, 38, 1019-1025.	0.9	11
40	Multiple sclerosis and HLA genotypes: A possible influence on brain atrophy. <i>Multiple Sclerosis Journal</i> , 2019, 25, 23-30.	1.4	11
41	The impact of deep grey matter volume on cognition in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102351.	0.9	11
42	The burden of multiple sclerosis variants in continental Italians and Sardinians. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1385-1395.	1.4	10
43	Long-term follow-up more than 10 years after HSCT: a monocentric experience. <i>Journal of Neurology</i> , 2018, 265, 410-416.	1.8	10
44	Association between brain atrophy and cognitive motor interference in multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 25, 208-211.	0.9	10
45	Pulse steroid therapy in multiple sclerosis and mood changes: An exploratory prospective study. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 20, 104-108.	0.9	9
46	Exploring cognitive motor interference in multiple sclerosis by the visual Stroop test. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 22, 8-11.	0.9	9
47	Does focal inflammation have an impact on cognition in multiple sclerosis? An MRI study. <i>Multiple Sclerosis and Related Disorders</i> , 2018, 23, 83-87.	0.9	9
48	MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study. <i>Journal of the Neurological Sciences</i> , 2021, 424, 117385.	0.3	9
49	Infections and Multiple Sclerosis: From the World to Sardinia, From Sardinia to the World. <i>Frontiers in Immunology</i> , 2021, 12, 728677.	2.2	7
50	A genetic association study of two genes linked to neurodegeneration in a Sardinian multiple sclerosis population: The TARDBP Ala382Thr mutation and C9orf72 expansion. <i>Journal of the Neurological Sciences</i> , 2015, 357, 229-234.	0.3	6
51	Is There Any Relationship between Upper and Lower Limb Impairments in People with Multiple Sclerosis? A Kinematic Quantitative Analysis. <i>Multiple Sclerosis International</i> , 2019, 2019, 1-6.	0.4	6
52	Quantifying gait impairment in individuals affected by Charcot-Marie-Tooth disease: the usefulness of gait profile score and gait variable score. <i>Disability and Rehabilitation</i> , 2020, 42, 737-742.	0.9	6
53	An unusual infection in MS patient treated with dimethyl fumarate: A case report of omphalitis. <i>Multiple Sclerosis and Related Disorders</i> , 2016, 7, 65-67.	0.9	5
54	Bipolar disorders and deep grey matter in multiple sclerosis: A preliminary quantitative MRI study. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 46, 102564.	0.9	5

#	ARTICLE	IF	CITATIONS
55	Oral Agents in Multiple Sclerosis. <i>Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry</i> , 2015, 14, 15-25.	1.1	4
56	Monoclonal Antibodies: A Target Therapy for Multiple Sclerosis. <i>Inflammation and Allergy: Drug Targets</i> , 2014, 13, 134-143.	1.8	4
57	Localized pigmentation disorder after subcutaneous pegylated interferon beta-1a injection. <i>Multiple Sclerosis Journal</i> , 2018, 24, 231-233.	1.4	3
58	Rescue therapy with alemtuzumab in multiple sclerosis post-natalizumab puerperium reactivation. <i>Neurological Sciences</i> , 2018, 39, 389-390.	0.9	3
59	The impact of modifiable risk factors on lesion burden in patients with early multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 39, 101886.	0.9	3
60	Long-term benefits of induction therapy in NMO: a case report. <i>Neurological Sciences</i> , 2014, 35, 1831-1832.	0.9	2
61	Harmonization of real-world studies in multiple sclerosis: Retrospective analysis from the rirems group. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 45, 102394.	0.9	2
62	The Dimethyl Fumarate Experience: A Handy Drug With Broad Clinical Utility. <i>Frontiers in Neurology</i> , 2021, 12, 679355.	1.1	2
63	A genetic study of the FMR1 gene in a Sardinian multiple sclerosis population. <i>Neurological Sciences</i> , 2015, 36, 2213-2220.	0.9	1
64	Facial synkinesis as a first symptom of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1499-1501.	1.4	1
65	Risk attitude and personality in people with multiple sclerosis facing the choice of different disease-modifying therapy scenarios. <i>Journal of the Neurological Sciences</i> , 2020, 417, 117064.	0.3	1
66	TARDBP Ala382Thr Mutation in Multiple Sclerosis: A Possible Role in Brain Atrophy. <i>Current Medical Imaging</i> , 2017, 14, 95-98.	0.4	0